Biogeba - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 6,160 | 4,942 | 13,733 | 14,534 | 16,265 | 26,018 | 23,111 | 56,588 |
| Profit before tax | 2,569 | 3,100 | 2,358 | 8,655 | 1,908 | 9,350 | 7,460 | 7,997 |
| Net profit | 2,184 | 2,945 | 2,240 | 8,220 | 1,812 | 8,882 | 7,087 | 7,517 |
| Equity | 8,272 | 7,241 | 9,192 | 17,412 | 16,226 | 15,109 | 15,846 | 15,364 |
| Liabilities | - | - | - | - | 2,594 | 1,393 | 2,927 | 1,167 |
| Non-current assets | 374 | 129 | 759 | 1,308 | 549 | 210 | 483 | 1,918 |
| Current assets | 9,926 | 7,961 | 21,946 | 18,135 | 18,271 | 16,292 | 18,290 | 14,613 |
| Total assets | 10,300 | 8,090 | 22,705 | 19,443 | 18,820 | 16,502 | 18,773 | 16,531 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 2,580 | 557 | 3,014 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +131.6% | -19.8% | +177.9% | +5.8% | +11.9% | +60.0% | -11.2% | +144.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 21.2% | 36.4% | 9.9% | 42.3% | 9.6% | 53.8% | 37.8% | 45.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 26.4% | 40.7% | 24.4% | 47.2% | 11.2% | 58.8% | 44.7% | 48.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 35.5% | 59.6% | 16.3% | 56.6% | 11.1% | 34.1% | 30.7% | 13.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 41.7% | 62.7% | 17.2% | 59.6% | 11.7% | 35.9% | 32.3% | 14.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 0.2 | 0.1 | 0.2 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | 14,534 | - | - | - | 56,588 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biogeba - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-05-16 | 2025-05-22 | 0.01 |
| 2022-12-01 | 2022-12-31 | 986.25 |
| 2022-11-18 | 2022-11-20 | 986.25 |
Biogeba - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biogeba, MB (code 303057625) is a Lithuanian small partnership engaged in research and experimental development on other natural sciences and engineering. In 2025, the latest financial year, the company generated revenue of €56.6K and net profit of €7.5K, with a profit margin of 13.3%. Revenue increased strongly from €23.1K in 2024 and €26.0K in 2023, showing a clear acceleration in turnover over the last year. Net profit was €7.1K in 2024 and €8.9K in 2023, so profitability remained positive throughout the period, although the margin declined as revenue expanded faster than profit. At the end of 2025, total assets stood at €16.5K, equity at €15.4K and liabilities at €1.2K, indicating a strongly equity-funded balance sheet. Key ratios for 2025 were ROE at 48.9%, ROA at 45.5%, debt-to-equity at 0.08 and asset turnover at 3.42x. Revenue per employee was €56.6K and profit per employee was €7.5K.